Ender Sirakaya

Ender Sirakaya

Auto-generated profile, based on publicly available information

Ender Sirakaya

Department of Ophthalmology, Kayseri City Training and Research Hospital, Health Science University, Kayseri, Turkey

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Indian Journal Of Ophthalmology
Verified
Journal Article
Open access
PDF file
ESEnder Sirakaya
Ender Sirakaya
ZDZeynep Duru
Zeynep Duru
BKBekir Kuçuk
Bekir Kuçuk
NDNecati Duru
Necati Duru
Purpose: To investigate monocyte to high-density lipoprotein (HDL) ratio (MHR) and neutrophil-to-lymphocyte ratio (NLR) as indicators of systemic inflammation in acute central serous chorioretinopathy (CSC). Methods: The HDL levels, hematological profiles, erythrocyte sedimentation rates (ESR), and C-reactive protein (CRP) levels of 38 patients with acute CSC (Group I) and 38 controls without CSC (Group II) were measured. Results: MHRs were significantly higher in Group I (13.30 ± 2.95) than in Group II (11.52 ± 2.42, P = 0.005), whereas NLRs, CRP values, and ESR values did not significantly differ between the groups (P = 0.726, P = 0.219, and P = 0.441, respectively). Multivariate analysis revealed that the MHR was an independent predictor of acute CSC (OR = 1.266, 95% CI = 1.054-1.521, P = 0.012). Conclusion: Indicating an association between increased MHRs and acute CSC, the MHR might represent simple, inexpensive, reliable biomarkers of inflammation in acute CSC.

18 March 2021 in Seminars in Ophthalmology
Verified
Journal Article
Closed access
OAOrhan Altunel
Orhan Altunel
ESEnder Sirakaya
Ender Sirakaya
This study investigated the quality of YouTube videos addressing multifocal intraocular lens (IOL) as educational resources.An online search of YouTube was performed for the terms “multifocal lens ...

20 August 2019 in International Ophthalmology
Verified
Journal Article
Closed access
PDF file
ESEnder Sirakaya
Ender Sirakaya
BKBekir Kucuk
Bekir Kucuk
AAAlperen Agadayi
Alperen Agadayi
NYNurhan Yilmaz
Nurhan Yilmaz

14 February 2020 in Current Eye Research
Verified
Journal Article
Closed access
ESEnder Sırakaya
Ender Sırakaya
BKBekir Küçük
Bekir Küçük
HSHatice Aslan Sirakaya
Hatice Aslan Sirakaya
Purpose: The aim of the study was to assess the amplitude of accommodation (AA) in patients with type 1 diabetes mellitus (DM) and without diabetic retinopathy. Materials and Methods: In two age- and sex-matched groups—one with twenty-nine eyes of 29 patients with type 1 DM, the other with twenty-nine eyes of 29 healthy individuals—retinal nerve fibre layer thickness and macular volume were determined by using optic coherence tomography in all quadrants, whereas AA was measured with the minus lens technique. The mean values of all three measurements were compared between the groups, and the effect of age, disease duration, HbA1c and fasting blood glucose on AA were analysed using multiple regression analysis. Results: On average, participants were 25.0 ± 3.3 years old (range 19–30) in both groups (P = 1.000), and patients had type 1 DM for an average of 13.0 ± 3.3 years. Mean AA in the right eye was 7.3 ± 1.1 D among patients and 8.1 ± 1.1 D among controls (P = 0.005), as well as significantly negatively correlated with age in both groups (r = -0.735, P < 0.001 and r = -0.819, P < 0.001, respectively) and disease duration among patients (r = -0.434, P = 0.019). In multivariable regression, age and disease duration significantly affected AA in patients, with an R2 value of 0.623 (P < 0.001 and P = 0.025, respectively). Average RNFL thickness was significantly different between the groups (P = 0.014). Mean macular volumes for areas 1, 3 or 5 mm in diameter were similar between the groups. Conclusions: AA was significantly lower among patients with type 1 DM than among healthy individuals, which suggests that the former might experience presbyopia earlier in life than the general population.

28 August 2019 in Ophthalmologica
Verified
Journal Article
Closed access
PDF file
ESEnder Sırakaya
Ender Sırakaya
BKBekir Küçük
Bekir Küçük
AAAlperen Ağadayı
Alperen Ağadayı
Purpose: The aim of this study was to compare responses to aflibercept treatment in age-based groups of patients with macular edema following branch retinal vein occlusion (BRVO). Methods: Eighty-five patients with macular edema following BRVO were divided into 4 groups according to their age: Group I (i.e., 45- to 54-year-olds), Group II (i.e., 55- to 64-year-olds), Group III (i.e., 65- to 74-year-olds), and Group IV (i.e., 75- to 84-year-olds). Each patient received a loading dose of 3 monthly intravitreal aflibercept injections. The treatment response was evaluated with visual acuity (VA) and optical coherence tomography measurements of the central foveal thickness (CFT), outer nuclear layer thickness (ONLT), and photoreceptor layer thickness (PRLT) before treatment and 1 month after the first and third injections. Results: In Group I (n = 19), Group II (n = 25), Group III (n = 23), and Group IV (n = 18), the mean values of VA, CFT, ONLT, and PRLT improved significantly 3 months after treatment. Whereas VA improved the most in Group I, its improvement significantly decreased in each progressively older age group, as did the reduction of the CFT, ONLT, and PRLT values, all of which were greater in groups I and II. Furthermore, age significantly correlated with changes in VA, CFT, ONLT, and PRLT across all groups. Conclusion: The efficacy and effectiveness of aflibercept treatment decrease in patients with macular edema following BRVO as they age, most likely due to age-related changes in posterior ocular structures.

13 November 2019 in Ocular Immunology and Inflammation
Verified
Journal Article
Closed access
BKBekir Küçük
Bekir Küçük
ESEnder Sirakaya
Ender Sirakaya
CKCagatay Karaca
Cagatay Karaca
Purpose: To compare the effectiveness of ranibizumab and aflibercept in macular edema (ME) with serous retinal detachment (SRD) following branch retinal vein occlusion (BRVO). Methods: Once every month for 3 months, 33 patients were treated with ranibizumab (Group 1), whereas 30 others were treated with aflibercept (Group 2). In 9 months after that, patients were evaluated every 4 weeks and received additional injections if they met prespecified criteria for retreatment. Corrected visual acuity (BCVA), central foveal thickness (CFT), and height of SRD was measured. Results: During the first 3 months, the improvement of CFT, BCVA, and height of SRD were greater in Group 2 than Group 1. Those differences disappeared in the subsequent 9 months, and changes in CFT, BCVA, and height of SRD were similar between groups at all other visits. Conclusion: Aflibercept was more effective than ranibizumab from baseline to Month 3 in ME with SRD following BRVO.